NCT00961480 - A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Co-administration of Sitagliptin and Metformin as Individual Tablets (0431A-095) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

November 30, 2007

Study Completion Date

November 30, 2007

Conditions

Type 2 Diabetes

Interventions

DRUG

sitagliptin phosphate (+) metformin hydrochloride

place holder - do not post

DRUG

Comparator: metformin 500mg

A single dose of metformin 500 mg tablet

DRUG

Comparator: sitagliptin

A single dose of 50 mg sitagliptin tablet

DRUG

Comparator: FMI sitagliptin / metformin 50 mg/500 mg FDC tablet

A single dose of FMI sitagliptin/metformin 50 mg/500 mg FDC tablet

DRUG

Comparator: FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet

A single dose of FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet

DRUG

Comparator: FMI sitagliptin/metformin 50 mg/850 mg FDC tablet

A single dose of FMI sitagliptin/metformin 50 mg/850 mg FDC tablet

DRUG

Comparator: metformin 1000 mg

A single dose of metformin 1000 mg tablet

DRUG

Comparator: metformin 850 mg

A single dose of metformin 850 mg tablet

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY